Advancing Clinical Research in Long QT Syndrome
Our clinical portfolio in Long QT Syndrome (LQTS) spans both interventional and observational research. The Wave studies assess the therapeutic potential of SGK1 inhibition, while myQTwave captures the lived experience of adults with LQTS Types 2 and 3 to help inform future innovation.
Together, these programs are shaping a new era of patient-centered progress in LQTS.
Please note: Our enrolling studies are currently open only to individuals residing in the United States.
The safety and efficacy of THRV-1268 have not yet been established. THRV-1268 has not been approved for commercial use by any regulatory authority (e.g. the FDA in the United States or Health Canada in Canada).